Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539929 | 1.00 | TAS1R3 (0.52) | TAS1R3TAS1R1CA2CA1CA12 | |
| SCHEMBL9716710 | 0.83 | ERAP2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL9716715 | 0.83 | ERAP2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL7034236 | 0.83 | LNPEP (0.60) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL7034241 | 0.83 | LNPEP (0.60) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL607886 | 0.83 | ITGB3 (0.60) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL607885 | 0.83 | ITGB3 (0.60) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL24518200 | 0.82 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL1767664 | 0.82 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 | |
| SCHEMBL6815759 | 0.82 | CA2 (0.55) | CA2CA1CA12CA9ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778846-B2 | Composition, device and associated method | GENERAL ELECTRIC COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778845-B2 | Composition, device and associated method | GENRAL ELECTRIC COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8765643-B2 | Composition, device and associated method | GENERAL ELECTRIC COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| US-8741813-B2 | Composition, device and associated method | GENERAL ELECTRIC COMPANY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140072956-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2014-03-13 | — | — | US | disclosed |
| US-20120122734-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122735-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122733-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2100142-B1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GEN ELECTRIC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2122351-B1 | COMPOSITION AND METHOD FOR THE DETECTION OF ANALYTES USING POLYMERIZATION BASED SIGNAL AMPLIFICATION | GEN ELECTRIC (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2122351-A2 | COMPOSITION AND METHOD FOR THE DETECTION OF ANALYTES USING POLYMERIZATION BASED SIGNAL AMPLIFICATION | General Electric Company (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2100142-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008127779-A2 | COMPOSITION AND METHOD FOR THE DETECTION OF ANALYTES USING POLYMERIZATION BASED SIGNAL AMPLIFICATION | GENERAL ELECTRIC COMPANY (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008070639-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122734-A1 | COMPOSITION, DEVICE AND ASSOCIATED METHOD | KIT, S100B, CACYBP | TAS1R3 3090/4885TAS1R1 2208/4885CA2 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.